Breast Cancer Detection Consortium

乳腺癌检测联盟

• 批准号: 9753167
• 负责人: Jeffrey R. Marks
• 金额: $ 42.37万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-19 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9753167
• 关键词: Algorithms; Area; Arizona; Autoantibodies; Benchmarking; Benign; Biological Markers; Biopsy; Blood; Breast; Breast Cancer Detection; Breast Microcalcification; Breast biopsy; CA-125 Antigen; Carcinoma in Situ; Cells; Clinical; Collaborations; Data; Decision Modeling; Detection; Diagnosis; Diagnostic; Diagnostic Procedure; Diagnostic radiologic examination; Digital Mammography; Disease; Early Diagnosis; Economics; Elements; Giant Cells; Goals; Image; Image Analysis; Immune response; Immunofluorescence Immunologic; Individual; Lead; Legal; Location; Malignant Neoplasms; Mammographic screening; Mammography; Measurement; Modality; Modernization; Needle biopsy procedure; Pathologic; Patients; Peptides; Performance; Phase; Population; Predictive Value; Procedures; Prospective Studies; Protein p53; Provider; Public Health; Recommendation; Risk; Sampling; Sensitivity and Specificity; Series; System; TP53 gene; Testing; Training; Ultrafiltration; United States; Universities; Validation; Whole Blood; Woman; Work; base; biomarker development; breast cancer diagnosis; breast imaging; cancer imaging; cancer invasiveness; cancer type; candidate marker; case control; circulating biomarkers; cost; density; design; digital; follow-up; imaging biomarker; imaging modality; imaging system; improved; innovation; laboratory development; macrophage; malignant breast neoplasm; mortality; multimodality; predictive marker; pressure; prevent; prospective; psychologic; screening; secondary endpoint

Abstract Mammography is an early detection modality for breast cancer that is implemented widely in the United States, has established benchmarks of performance, and in most studies throughout the world has been demonstrated to reduce mortality due to the disease. This relatively inexpensive x-ray imaging of the breast also provides a location that can be directly sampled through needle biopsy which leads generally to an unambiguous pathologic diagnosis of invasive cancer, carcinoma in situ, or benign findings. No system is perfect and mammographic screening, particularly in the US, prompts over 1.6 million biopsies per year detecting approximately 230,000 invasive and 60,000 non-invasive cancers for a positive predictive value of less than 20%. There may be substantial room to improve on this and reduce the number of biopsies but this improvement must not sacrifice detection rates so the negative predictive value (NPV, identification of true negatives) must remain very high. In this Biomarker Development Laboratory application, we propose to test whether a combination of mammographic feature analysis and candidate biomarkers that we have identified can achieve an NPV that would be acceptable to patients and providers to prevent unnecessary breast biopsies. One of the biomarkers is a type of circulating giant cell termed “Cancer Associated Macrophage Like” (CAML) that can only be detected using freshly drawn whole blood, we propose to conduct a prospective trial at Duke University in women undergoing breast cancer diagnosis. Our realistic goal is to accrue ~1000 women over the course of 4 years for which full field digital mammography has been performed. The images will undergo feature extraction for decision modeling. Blood will be analyzed for the presence and type of CAML cells, immunosignaturing using the high density peptide arrays developed by Stephen Johnston at Arizona State, and measurements of two specific analytes that have the highest sensitivity and specificity for basal type cancers, CA125 and TP53 autoantibodies. As feature analysis from imaging alone can achieve, at least for masses on mammography, an AUC of ~0.9, the study is designed to determine whether the biomarkers have sufficient complementary information to the imaging and each other to increase the AUC to 0.95 allowing us to identify a threshold where there is a 98% NPV. We will make use of the most careful and consistent standard operating procedures, the best candidate biomarkers, and the most well developed imaging algorithms to make this a definitive study.

摘要